Responses
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
